题名

緊急的倫理：新型冠狀肺炎疫苗之臨床試驗及緊急授權的法制與倫理分析

并列篇名

Ethics of Emergency: An Anatomy of Legal and Ethical Issues of Clinical Research and Emergency Use Authorization of COVID-19 Vaccines

DOI

10.6199/NTULJ.202111/SP_50.0001

作者

張兆恬(Chao-Tien Chang)

关键词

新冠病毒 ； 疫苗 ； 公衛倫理 ； 公衛緊急狀態 ； 臨床試驗倫理 ； 人體研究倫理 ； 緊急授權 ； 司法院釋字第690號解釋 ； 藥事法 ； COVID-19 ； vaccine ； public health ethics ； public health emergency ； clinical research ethics ； human subjects ethics ； emergency use authorization ； J.Y. Interpretation No. 690 ； Pharmaceutical Affairs Act

期刊名称

臺大法學論叢

卷期/出版年月

50卷S期（2021 / 11 / 01）

页次

1073 - 1165

内容语文

繁體中文
中文摘要

新冠疫苗以前所未見的速度成為抗疫措施之一，然而其研發與審查過程也帶來管制與倫理的挑戰，本文以緊急狀態下的公衛倫理為立基加以檢視。緊急狀態下的公衛倫理，以減少傷害和保障公共衛生為目標，且容許公衛措施非必然符合最小侵害原則，但同時亦須強化決策的透明、包容、責信，以及符合平等與正義原則，並以回復常態為目標。就新冠疫苗的臨床試驗而言，雖有出現為了促進研發而容許倫理爭議的試驗方式，然而在國際實踐上，最終仍以受試者保護為優先。又就緊急授權的審查上，美國政府採取較嚴格的審查標準及程序，以回應公眾對於新冠疫苗研發縮時的疑慮。可見在疫情的緊急狀態下，個人健康與生命權的保護、程序正當性、責信更形重要，此亦與緊急公衛倫理相呼應。我國防疫法制中，向來傾向仰賴醫療與公衛專業，而以立法概括授權行政機關。惟我國國產疫苗的研發與審核，不僅涉及科學證據，更須進行政治判斷，故依據緊急的公衛倫理，應該加強決策程序的透明性、政府的責信。雖然新冠疫情可能帶來公衛與管制的新常態，但緊急的公衛倫理亦揭示須堅守核心的倫理價值。
英文摘要

Serving as one of the major pandemic prevention measures, the COVID-19 vaccines create a new paradigm of an unprecedently efficient research and development (R&D) and review process. However, the new paradigm also brings new regulatory and ethical issues. This article examines the regulatory and ethical challenges through the lens of public health ethics in emergency (PHEE). PHEE sets alleviating harms and protecting public health as the primary concerns, while it tolerates governmental interventions not necessarily least restrictive. PHEE also highlights the decision-making process to be transparent, inclusive and accountable. In addition, equity, justice, and preparation for returning to normalcy are also the core PHEE principles. PHEE coincides with legal and ethical practices in the COVID-19 R&D and review process. In terms of the clinical research of COVID-19 vaccines, international practices remain to consider human subjects protection as the priority, regardless of calls for a loosened ethical standard for the purpose of speeding up research during the pandemic. With regards to emergency use authorization (EUA), the US government took an ＂EUA plus＂ standard, in response to public doubts about safeness and effectiveness of the vaccines invented within a condensed timeline. Echoing with PHEE, the abovementioned issues concerning COVID-19 vaccine research and EUA indicate that the protection of individual health and life, due process, and accountability are irreparable even under public health emergency. The pandemic law of Taiwan has been deferential to medical and public health expertise, that is, the legislation grants blanket authorization to the executive branch. However, the R&D and EUA of domestic vaccines of Taiwan are not simple decisions based on scientific evidence, but involve complicated political judgements. The legal and policy suggestion based on PHEE is to strengthen transparency and accountability in the decision-making process. To conclude, while COVID-19 is likely to bring a new normal to public health and regulation, PHEE urges the obligation to adhere to the core of ethics.
主题分类 社會科學 > 法律學
参考文献
  1. Adashi, E. Y.,Rajan, R. S.,Cohen, I. G.(2019).When Science and Politics Collide: Enhancing the FDA.Science,364(6441),628-631.
  2. Allen, D.,Stanczyk, L.,Cohen, I. G.,Shachar, C.,Sethi, R.,Weyl, G.,Brooks., R.(2020).,Edmond J. Safra Center for Ethics.
  3. Anomaly, J.,Savulescu, J.(2019).Compensation for Cures: Why We Should Pay a Premium for Participation in ‘Challenge Studies’.Bioethics,33(7),792-797.
  4. Bayer, R.,Fairchild, A. L.(2004).The Genesis of Public Health Ethics.Public Health Law and Ethics: A Reader
  5. Blum, J. D.,Paradise, J.(2018).Public Health Preparedness & Response: An Exercise in Administrative Law.The DePaul Journal of Health Care Law,20(2),1-21.
  6. Borah, R.(2020).Every Minute Matters: Improving the Regulatory Response to Vaccine Development During a Public Health Emergency.Food and Drug Law Journal,75(2),311-345.
  7. Brown, B. (2020, Oct. 30). Ethics of Emergency Use Authorization During the Pandemic. The Hastings Center. https://www.thehastingscenter.org/ethics-of-emergency-use-authorization-during-the-pandemic/
  8. Callahan, D.,Jennings, B.(2002).Ethics and Public Health: Forging a Strong Relationship.Public Health Law and Ethics: A Reader
  9. Cammet, M., & Lieberman, E. (2020). Building Solidarity: Challenges, Options, and Implications for Covid-19 Responses. https://ethics.harvard.edu/building-solidarity
  10. Chang, W. C. (2020, Mar. 21). Taiwan’s fight against COVID-19: constitutionalism, laws, and the global pandemic. Verfassungsblog. https://verfassungsblog.de/taiwans-fight-against-covid-19-constitutionalism-laws-and-the-global-pandemic/.
  11. Chernoguz, J. (2020, Mar. 25). Protecting Rights in a Global Crisis. Harvard Law Today. https://today.law.harvard.edu/protecting-rights-in-a-global-crisis/.
  12. Coglianese, C. (2020, Apr. 20). Obligation Alleviation During the COVID-19 Crisis. Regulatory Review. https://www.theregreview.org/2020/04/20/coglianese-obligation-alleviation-during-covid-19-crisis/
  13. Coglianese, C.,Scheffler, G.,Walters, D. E.(2021).Unrules.Stanford Law Review,73(4),885-967.
  14. Council for International Organizations of Medical Sciences(2016).International Ethical Guidelines for Health-Related Research Involving Humans.CIOMS.
  15. Deming, M. E.,Michael, N. L.,Robb, M.,Cohen, M. S.,Neuzil, K. M.(2020).Accelerating Development of SARS-CoV-2 Vaccines: the Role for Controlled Human Infection Models.New England Journal of Medicine,383(10),e63.
  16. Eyal, N.(2020).Why Challenge Trials of SARS‐ CoV‐ 2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.Ethics & Human Research,42(4),24-34.
  17. Eyal, N.,Lipsitch, M.,Smith, P. G.(2020).Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.The Journal of Infectious Diseases,221(11),1752-1756.
  18. Flore, E. F.,Frontera, W. R,Andrasik, M. P.,Rio, C.,Mondríguez-González, A.,Price, S. A.,Krantz, E. M.,Pergam, S. A.,Silver, J. K.(2021).Assessment of the Inclusion of Racial/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials.JAMA Network Open,4(2),1-11.
  19. Friesen, P.,Caplan, A. L.,Miller, J. E.(2021).COVID-19 Vaccine Research and the Trouble with Clinical Equipoise.Lancet,397(10274),576-577.
  20. Ganz, D. J.(2020).Reconsidering Discretion in Expedited Vaccine Approval in Light of the Novel Coronavirus.University of Illinois Law Review Online,2020,203-220.
  21. Ginsburg, T. & Versteeg, M. (2020). State of emergencies: Part I. Harvard Law Review Blog, https://blog.harvardlawreview.org/states-of-emergencies-parti/
  22. Gostin, L. O.(Ed.)(2010).Public Health Law and Ethics: A Reader
  23. Gostin, Lawrence O.,Wiley, Lindsay F.,蘇玉菊（譯）,劉碧波（譯）,穆冠群（譯）(2019).公共衛生法：權力、責任、限制.元照.
  24. Gouglas, D.,Le, T. T.,Henderson, K.,Kaloudis, A.,Danielsen, T.,Hammersland, N. C.,Robinson, J. M.,Heaton, P. M.,Røttingen, J.(2018).Estimating the Cost of Vaccine Development Against Epidemic Infectious Diseases: a Cost Minimisation Study.The Lancet Global Health,6(12),e1386-e1396.
  25. Grady, C.(2004).Ethics of Vaccine Research.Nature Immunology,5(5),465-468.
  26. Hermes, C.,Wethington, N.(2020).Balancing Hope and Proof: Investigational Products During the COVID-19 Pandemic.Health Lawyer,33(2),6-9.
  27. Hodge, J. G.,Piatt, J. L.,Reinke, H. N.,Carey, E.(2021).COVID’s Constitutional Conundrum: Assessing Individual Rights in Public Health Emergencies.Tennessee Law Review,88(1)
  28. Hsu, N. S.,Hendriks, S.,Ramos, K. M.,Grady, C.(2021).Ethical Considerations of COVID-19-Related Adjustments to Clinical Research.Nature Medicine,27(2),191-193.
  29. Jennings, B.,Arras, J. D.(2016).Ethical Aspects of Public Health Emergency Preparedness and Response.Ethical Aspects of Public Health Emergenc Emergency Ethics: Public Health Preparedness and Response
  30. Johnson, E. E.,Bailey, T. C.(2020).Legal Lessons from a Very Fast Problem: COVID-19.Stanford Law Review Online,73,89-103.
  31. Karako-Eyal, N.(2019).Beyond the Ethical Boundaries of Solidarity: Increasing Vaccination Rates Through Mandatory Education to Solidarity.Texas A&M Law Review,6(2),345-390.
  32. Krammer, F.(2020).SARS-CoV-2 Vaccines in Development.Nature,586(7830),516-527.
  33. Largent, E. A.(2016).EBOLA And FDA: Reviewing the Response to the 2014 Outbreak, to Find Lessons for the Future.Journal of Law and Biosciences,3(3),489-537.
  34. Lee, K., & Eyal, N. (2021, May 13). Do Controlled Human Infection Studies Put Bystanders at Higher Risk Than Conventional Field Trials?. Journal of Medical Ethics Blog. https://blogs.bmj.com/medical-ethics/2021/05/13/do-controlled-human-infection-studies-put-bystanders-at-higher-risk-than-conventional-field-trials/
  35. Lin, C.,WU, C.,WU, C.(2020).Reimagining the Administrative State in Times of Global Health Crisis: An Anatomy of Taiwan’s Regulatory Actions in Response to the COVID-19 Pandemic.European Journal of Risk Regulation,11(2),256-272.
  36. London, A. J.,Kimmelman, J.(2020).Against pandemic research exceptionalism.Science,368(6490),476-477.
  37. Lurie, N.,Cramer, J. P.,Hatchett, R. J.(2021).The Vaccine Revolution: How mRNA Can Stop the Next Pandemic Before It Starts.Foreign Affairs,100(3),128-135.
  38. Lynch, H. F., Darton, T., Largent, E. A., Levy, J., McCormick, F., Ogbogu, U., Payne, R., Roth, A. E., Shah, A. J., & Smiley, T. (2020). Ethical Payment to Participants in Human Infection Challenge Studies, With a Focus on Sars-Cov-2: Report and Recommendations. https://doi.org/10.2139/ssrn.3674548
  39. Lynch, H. F.,Dickert, N. W.,Zettler, P. J.,Joffe, S.,Largent, E. A.(2020).Regulatory Flexibility for COVID-19 Research.Journal of Law and the Biosciences,7(1),1-10.
  40. Lynch, H. F.,Joffe, S.,McCoy, M. S.(2021).The Limits of Acceptable Political Influence over the FDA.Nature Medicine,27(2),188-190.
  41. Macklin, R. (2020, Jun. 15). Human Challenge Studies for Covid-19 Vaccine: Questions About Benefits and Risks. The Hastings Center. https://www.thehastingscenter.org/human-challenge-studies-for-covid-19-vaccine-questions-about-benefits-and-risks/.
  42. Miller, F. G. (2020, Oct. 27). Ethics of Placebo Controls in Coronavirus Vaccine Trials. The Hastings Center. https://www.thehastingscenter.org/ethics-of-placebo-controls-in-coronavirus-vaccine-trials/.
  43. National Academies of Sciences, Engineering, and Medicine(2017).Integrating Clinical Research into Epidemic Response: the Ebola Experience.The National Academies Press.
  44. Nguyen, X.(2021).Contract as Emergency Law.Washington International Law Journal,30(3),420-469.
  45. Nuffield Council on Bioethics(2020).Nuffield Council on Bioethics. (2020). Research in Global Health Emergencies: Ethical Issues..
  46. Paradise, J.,Bavlsik, B.(2021).Pandemic Politics, Public Health, and the FDA.Belmont Law Review,8(2),301-341.
  47. Plotkin, S. A.,Caplan, A.(2020).Extraordinary Diseases Require Extraordinary Solutions.Vaccine,38(24),3987-3988.
  48. Prainsack, B.,Buyx, A.(2011).Solidarity: Reflections on an Emerging Concept in Bioethics.Nuffield Council on Bioethics.
  49. Reiss, D. R.(2020).The COVID-19 Vaccine Dilemma.The Administrative Law Review Accord,6(1),49-83.
  50. Rizzi, M.(2020).The Road to a Vaccine for COVID-19: Regulatory and Policy Infrastructure, Incentives and Obstacles.European Pharmaceutical Law Review,4(2),98-103.
  51. Shah, A.,Marks, P. W.,Hahn, S. M.(2020).Unwavering Regulatory Safeguards for COVID-19 Vaccines.JAMA,324(10),931-932.
  52. Sherwin, B. D.(2021).Anatomy of a Conspiracy Theory: Law, Politics, and Science Denialism in the Era of COVID-19.Texas A&M Law Review,8(3),537-582.
  53. Singh, J. A.,Kochhar, S.,Wolff, J.(2021).Placebo Use and Unblinding in COVID-19 Vaccine Trials: Recommendations of a WHO Expert Working Group.Nature Medicine,27(4),569-570.
  54. Solbakk, J. H.,Bentzen, H. B.,Holm, S.,Heggestad, A.K. T.,Hofmann, B.,Robertsen, A.,Alnæs, A. H.,Cox, S.,Pedersen, R.,Bernabe, R.(2021).Back to WHAT? The Role of Research Ethics in Pandemic Times.Medicine, Health Care and Philosophy,24(1),3-20.
  55. Steel, R.,Buchak, L.,Eyal, N.(2020).Why Continuing Uncertainties Are No Reason to Postpone Challenge Trials for Coronavirus Vaccines.Journal of Medical Ethics,46(12),808-812.
  56. Steinzor, R. (2020, Sept. 14). The pandemic’s toll on science. Regulatory Review. https://www.theregreview.org/2020/09/14/steinzor-pandemic-toll- science/
  57. Sturgis, P.,Brunton-Smith, I.,Jackson, J.(2021).Trust in Science, Social Consensus and Vaccine Confidence.Nature Human Behaviour
  58. United States National Commission for the Protection of Human Subjects of Biomedical, & Behavioral Research(1978).The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.
  59. Walsh, D.(2021).COVID-19: A Crisis and an Opportunity to Improve the Emergency Use Authorization Process.Minnesota Journal of Law, Science & Technology,22(2),169-220.
  60. Whelan, A. M.(2021).Unequal Representation: Women in Clinical Research.Cornell Law Review Online,106(3),87-128.
  61. WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation(2021).Placebo-Controlled Trials of Covid-19 Vaccines: Why We Still Need Them.New England Journal of Medicine,384(2),e2(1)-e2(3).
  62. Wiley, L. F.,Bagenstos, S. R.(2020).The Personal Responsibility Pandemic: Centering Solidarity in Public Health and Employment Law.Arizona State Law Journal,52(4),1235-1302.
  63. Witt, J. F. (2020, Mar. 30). The Law of Salus Populi: Epidemics and the Law. Yale Review. https://yalereview.org/article/law-salus-populi
  64. Yearby, R.,Mohapatra, S.(2020).Law, Structural Racism, and the COVID-19 Pandemic.Journal of Law and Biosciences,7(1),1-20.
  65. 吳秦雯(2020)。從 SARS 到 COVID-19：司法院釋字第 690 號解釋架構下之傳染病防治法制與基本權限制。法律與生命科學，9(1)，91-112。
  66. 李建良(2011)。人身自由的憲法保障與強制隔離的違憲審查：釋字第690 號解釋。台灣法學雜誌，186，60-79。
  67. 李建良(2020)。在瘟疫中思索自由。人文及社會科學簡訊，22(1)，30-33。
  68. 林明昕(2021)。再論嚴重特殊傳染性肺炎防治及紓困振興特別條例第 7條之合憲性爭議。台灣法學雜誌，407，53-68。
  69. 林欣柔(2020)。新冠肺炎流行下的公衛權力與界限。法律與生命科學，9(1)，67-89。
  70. 邱文聰,吳全峰,劉靜怡,劉定基,翁逸泓(2021)。科技防疫與個人資料保護（下）。月旦裁判時報，107，88-104。
  71. 施明遠(2021)。從公共衛生危機到國家安全意識：美國醫療對應措施立法之演進與分析。月旦法學雜誌，312，46-69。
  72. 徐千惠,吳馥羽,吳彥慧(2020)。人體攻毒試驗應用於疫苗研發：過去、今日與未來。當代醫藥法規月刊，120，1-17。
  73. 許育典(2021)。不同於憲法緊急狀態的法治國防疫措施：以法治國的國家保護義務為核心。月旦法學雜誌，314，182-190。
  74. 陳仲嶙(2020)。從防疫出國禁令爭議再訪法律保留的疆界。法律與生命科學，9(1)，1-37。
  75. 陳嘉新(2020)。防疫共同體的生命政治。臺灣社會學刊，67，237-246。
  76. 詹祐維(2020)。傳染病防治法強制隔離措施之檢討：以釋字 690 號解釋為中心。萬國法律，231，12-23。
  77. 雷文玫(2021)。防疫共同體的物資整備：從我國口罩光榮動員經驗看下一波超前部署所需要的法制整備。月旦法學雜誌，312，23-45。
  78. 劉宏恩(2020)。評我國食藥署關於 COVID-19 疫苗臨床試驗受試者徵求及緊急授權使用（EUA）之政策。生物醫學，13(4)，237-239。
被引用次数
  1. 許鴻基(2023)。緊急使用授權之「緊急」－從美國法上觀察我國法制之修正建議。軍法專刊，69(3)，90-130。
  2. 葉明叡,吳建昌(2022)。傳染病大流行時的公共衛生研究倫理：兼論特殊研究倫理審查機制之芻議。政治與社會哲學評論，77，1-58。
print cancel